Novartis Leads the Pack

Europe's got 'em. Now Japan has 'em. When will the U.S. follow suit?

We're talking about follow-on biologics, also known as "biosimilars," depending on the country of origin. Novartis (NYSE: NVS  ) said yesterday that it had received approval of the first biosimilar in Japan. The drug, somatropin, is a generic version of Pfizer's (NYSE: PFE  ) human growth hormone, Genotropin.

Technically, Japan isn't ahead of the U.S. While the U.S. doesn't have a pathway for approval of follow-on biologics, the Food and Drug Administration has let one through: the same human growth hormone that Japan just approved, which is marketed under the name Omnitrope. But Novartis had to sue the government to finally get the drug approved, and no other company has tried a similar tactic that I know of.

But Japan will surely pass us up since the country has established a pathway for approval. In fact it only took about three months for the country to approve the first biosimilar after the government published guidelines for companies. I expect Amgen (Nasdaq: AMGN  ) and Johnson & Johnson's (NYSE: JNJ  ) anemia drugs to be the next target, as they were when Europe opened up its process for approvals. And Hospira (NYSE: HSP  ) and Teva Pharmaceuticals (Nasdaq: TEVA  ) , among others, are likely to be hot on Novartis' tail.

In the U.S., the main hang-up is how much guaranteed patent protection branded biologics will be given. Biotech companies want 12 to 14 years of protection, the Federal Trade Commission thinks five years is sufficient, and yesterday the White House said seven years was enough. How many years biotech companies will get remains to be seen, but it's clear that the question is when we'll have a pathway for approval, not if.

Investors looking to take advantage of this billion-dollar industry that's about to open up should take a good look at Novartis. The company is clearly at the forefront of the biosimilar development and I expect it'll be at the front of the line when the U.S. opens its doors.

Follow-on Foolishness:

Pfizer is a Motley Fool Inside Value recommendation. Johnson & Johnson is an Income Investor pick. Novartis is a Global Gains selection. Try any of our Foolish newsletters today, free for 30 days.

Fool contributor Brian Orelli, Ph.D., doesn't own shares of any company mentioned in this article. The Fool has a disclosure policy.


Read/Post Comments (1) | Recommend This Article (9)

Comments from our Foolish Readers

Help us keep this a respectfully Foolish area! This is a place for our readers to discuss, debate, and learn more about the Foolish investing topic you read about above. Help us keep it clean and safe. If you believe a comment is abusive or otherwise violates our Fool's Rules, please report it via the Report this Comment Report this Comment icon found on every comment.

  • Report this Comment On October 27, 2009, at 8:40 AM, rachelchu wrote:

    For anyone interested in further reading on the issue of biosimilars, see the Stockholm Network's latest paper in its series on patient safety: Biogenerics or Biosimilars? Discussing the Present, Considering the Future.

    In this paper, Rachel Chu and Dr Meir Pugatch explore the issue of biosimilars and their impact on healthcare policymaking. They examine the various challenges that the advent of biosimilars raises, particularly with regard to the regulatory framework, market opportunities, IPRs and most importantly of all, with regard to public safety.

    The paper takes four of the most relevant pathways as case studies, namely the EU, WHO, Canada and the US (where legislation is still under way), and evaluates in particular whether these pathways have resolved the safety and IP dilemmas. Finally, it presents several policy recommendations, which should allow more clarity and predictability for those wishing to enter the market as well as providing enhanced scientific rigour, in the interests of patients.

    To view the paper, please visit:

    http://www.stockholm-network.org/downloads/publications/Bios...

    To view the executive summary, please visit:

    http://www.stockholm-network.org/downloads/publications/Bios...

Add your comment.

Sponsored Links

Leaked: Apple's Next Smart Device
(Warning, it may shock you)
The secret is out... experts are predicting 458 million of these types of devices will be sold per year. 1 hyper-growth company stands to rake in maximum profit - and it's NOT Apple. Show me Apple's new smart gizmo!

DocumentId: 929745, ~/Articles/ArticleHandler.aspx, 10/20/2014 4:55:14 AM

Report This Comment

Use this area to report a comment that you believe is in violation of the community guidelines. Our team will review the entry and take any appropriate action.

Sending report...


Advertisement